Latest Breaking News On - Moderna chief medical officer tal zaks - Page 1 : comparemela.com
Moderna s mRNA dreams meet reality with first post-Covid shot
boston.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boston.com Daily Mail and Mail on Sunday newspapers.
Moderna s mRNA Dreams Meet Reality With First Post-Covid Shot
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
Wharton Undergraduate Healthcare Conference addresses impact of COVID-19 on health care
thedp.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedp.com Daily Mail and Mail on Sunday newspapers.
Israel Summit Targets Non-Jews on Campus
Israel Summit Targets Non-Jews on Campus
The goal of the virtual summit is to broaden Israel’s appeal to those who don’t have a vested interest in the country. By Jan Jaben-Eilon January 27, 2021, 1:19 pm Edit 68 shares
It’s one thing to advocate on Israel’s behalf to Jewish university students. It’s quite another to share Israel’s story with the non-Jewish students.
That larger audience is the target of next month’s virtual Israel Summit, an international conference organized by university students around the world. Harvard sophomore Aidan Golub, the executive director of The Israel Summit, said his goal is to “change the conversation about Israel on campus. We have Jewish organizations that run Israel programming targeted to Jews, but for the other 97 percent of the students who don’t have the exposure, Israel is merely synonymous with the desert, apartheid weeks and violence.
Science’
s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.
News from U.S. manufacturer Moderna that its COVID-19 vaccine is still “expected to be protective” against a virus variant first detected in South Africa came as a relief to scientists and the public. But the 25 January announcement included a caveat: Antibodies triggered by the vaccine appear to be a little less potent against the new variant, named B.1.351, than the one the vaccine was developed for. So researchers were perhaps even more relieved to hear the company will start development of booster shots tailored to B.1.351 and other variants.